<p>Lung cancer cell lines were treated with EGFR-specific-siRNA 1247. Live cells and apoptotic cells were detected with Hoechst 33342 and PI double fluorescent staining. The number of apoptotic cells was normalized to the number of live cells in the same well. Hoechst 33342 and PI double fluorescent staining ×200.</p
Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epi...
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR)...
, cells cultured with 10 nM FVIIa were treated with different concentrations of either TF siRNA or c...
The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung...
<p><b>A</b>, Radio-sensitivity assay of cells treated with EGFR and IGF1R inhibitors. Cancer cells o...
BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-sma...
Epidermal Growth Factor Receptor (EGFR) has long been considered an important oncogene for the growt...
To clarify the pathogenic and biological significance of EGFR mutations in lung cancer, we compared ...
The Epidermal Growth Factor Receptor (EGFR) and its mutations contribute in various ways to tumorige...
The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In ...
To clarify the pathogenic and biological significance of EGFR mutations in lung cancer, we compared ...
AIM: To investigate the biological features of A549 cells in which epidermal growth factor (EGF) rec...
The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In ...
<div><p>The Epidermal Growth Factor Receptor (EGFR) and its mutations contribute in various ways to ...
<p><b>Copyright information:</b></p><p>Taken from "Responses of cancer cells with wild-type or tyros...
Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epi...
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR)...
, cells cultured with 10 nM FVIIa were treated with different concentrations of either TF siRNA or c...
The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung...
<p><b>A</b>, Radio-sensitivity assay of cells treated with EGFR and IGF1R inhibitors. Cancer cells o...
BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-sma...
Epidermal Growth Factor Receptor (EGFR) has long been considered an important oncogene for the growt...
To clarify the pathogenic and biological significance of EGFR mutations in lung cancer, we compared ...
The Epidermal Growth Factor Receptor (EGFR) and its mutations contribute in various ways to tumorige...
The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In ...
To clarify the pathogenic and biological significance of EGFR mutations in lung cancer, we compared ...
AIM: To investigate the biological features of A549 cells in which epidermal growth factor (EGF) rec...
The epidermal growth factor receptor (EGFR) is an important novel target for anticancer therapy. In ...
<div><p>The Epidermal Growth Factor Receptor (EGFR) and its mutations contribute in various ways to ...
<p><b>Copyright information:</b></p><p>Taken from "Responses of cancer cells with wild-type or tyros...
Gefitinib (Iressa, Astra Zeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epi...
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR)...
, cells cultured with 10 nM FVIIa were treated with different concentrations of either TF siRNA or c...